Empowered by the successful closure of our Series-A Financing Round counting 14.5 million CHF, we are boosting our path to market entry for the Surgical-Fiberlock™ technology!

For more information, please read our press release.

Important step toward expansion for ZuriMED Technologies AG

We are thrilled to announce, that we received the Innosuisse Scale-up Award! After an intensive phase, where we presented our objectives and concept for commercial growth to a committee of experts and representatives of the Innosuisse Innovation Council, we got a positive evaluation and we were granted the award. Thanks to this recognition, we can access the second phase of the Scale-up Coaching program to further accelerate our growth in Switzerland and to expand into new global markets with the support of specialized Innosuisse coaches. They will also assist us in different areas whereas organizational growth and scaling, regulatory affairs, or fundraising and investor relations and more. Additionally, we will benefit from an internationalization offers during 2 years.

We would like to thank Innosuisse and especially Innosuisse’s coaches Pierre Comte, Daniel Brandenburger, Anna Sumeray and Laurent Grandidier for their continual support. We highly appreciate all the work and efforts put into our expansion!

More News

The Zurich based startup ZuriMED, specialising in orthopaedic biomechanics, has earned the Innosuisse certificate, thanks to its revolutionary device for ligament reconstruction. The company’s Bone-Tendon-Bone (BTB)-Converter™ is currently undergoing a clinical trial.

Founded in 2015, ZuriMED is developing a device for surgical knee ligament reconstruction, the BTB-Converter™. The idea behind the new surgical technique it to effectively convert a less painful hamstring autograft (a patient’s own tissue), or any other flexible graft, into a higher performance BTB-like graft. According to Xiang Li, Co-founder and CEO of ZuriMED, there has been a change from the original design in the product development. He says, “Due to the EU regulatory environment transition, our original strategy of having a complete, preassembled BTB-Conversion-Kit™ has changed: we would now have two separate implants, which could be assembled during surgery.”

The first component of the kit, the BTB-Converter™ is currently under clinical trial at University Hospital Balgrist, which started in 2017, and is scheduled to complete by early 2021. The second component, the product VariLoop™ is expected to enter into clinical trial next year.”

The company has now obtained the Innosuisse certificate in recognition for the potential of its technology and solutions. In acknowledgement of the receipt of this accolade, Xiang comments: “We see the Innosuisse certificate as a valuable label accredited by external experts for the work we have done in the past. Besides being a label that we could proudly present to our current investor, we believe that this certificate would certainly help us during the due diligence for a potential future financing round.”

More news

For the 4th time, the venture leaders jury has selected the venture leaders China team 2017, forming the “Swiss National Startup Team China”.

Visit the website.

ZuriMED Technologies AG won the competition with the Project “A Novel Medical Device for Ligament Reconstruction”.

Visit the website.

The Commission for Technology and Innovation (CTI) granted a collaboration project for a clinical Trial at the Balgrist Univeristy Hospital.